Neoadjuvant chemotherapy combining docetaxel, cisplatin and S-1 in gastric cancer with para-aortic lymph node metastases: Report of five cases

Hepato-Gastroenterology

Volumn 57, Issue 104, 2010, Pages 1650-1654

  Fushida, Sachio ^a   Fujimura, Takashi ^a   Oyama, Katsunobu ^a   Kinoshita, Jun ^a   Fujita, Hideto ^a   Ninomiya, Itasu ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Docetaxel; Gastric cancer; Neoadjuvant chemotherapy; Para aortic lymph node metastases; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; CORTICOSTEROID; DOCETAXEL; SEROTONIN 3 ANTAGONIST;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYPOHEMOGLOBINEMIA; LYMPH FLOW; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARAAORTIC LYMPH NODE METASTASIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STOMACH CANCER; TOTAL STOMACH RESECTION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; GASTRECTOMY; GASTROSCOPY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79952364858     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974.
2. Ajani JA, Mansfield P, Janjan N, et al.: Multünstitutional trial of preoperative chemoradiotherapy in patients with potentially respectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-2780. (Pubitemid 41079894)
3. Harris BE, Song R, Soong ST, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201. (Pubitemid 20030018)
4. Shirasaka T, Shimamoto Y, Ohshimo H et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557. (Pubitemid 26276346)
5. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxalic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009. (Pubitemid 23267702)
6. Sugimachi K, Maehara Y: The S-1 gastrointestinal cancer study group: an early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57: 202-210. (Pubitemid 29481693)
7. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58: 191-197. (Pubitemid 30189900)
8. Webb A, Cuningham D, Scarffe JH et al.: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophago-gastric cancer. J Clin Oncol 1997; 15: 261-267. (Pubitemid 27020582)
9. Waters JS, Norman A, Cuningham D et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269-272. (Pubitemid 29210117)
10. Kelsen D, Atiq OT, Saltz L et al.: FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
11. Lenz HJ, Lee FC, Haller DG et al.: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109: 33-40/
12. Koizumi W, NaraharaH, Hara T et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
13. Yoshida K, Ninomiya M, Takakura N et al.: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3042-3047.
14. Park SR, Kim HK, Kim CG et al.: Phase I/II study of combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer 98: 1305-1311.
15. Nishi M, Omori Y, Miwa Y: Response Assessment of Chemotherapy and Radiotherapy for Gastric Carcinoma Part IV, Kanehara Shuppan, Tokyo, Japan, 1999: 89-100.
16. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M et al.: Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended paraaortic lymphadenectomy-Japan Clinical Oncology Froup study 9501. J Clin Oncol 2004; 22: 2767-2773. (Pubitemid 41079893)
17. Yoshikawa T, Sasako M, Sano T, Nashimoto A, Kurita A, Tsujinaka T et al.: Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from results prospective randomized controlled trial. Br J Surg 2006; 93: 1526-1529. (Pubitemid 44893655)
18. Kawashima Y, Sasako M, Tsuburaya A, Sano T, Tanaka Y, Nashimoto A: Gastric surgery group in Japanese clinical oncology group: Phase II study of preoperative neoadjuvant chemotherapy with S-1 plus cisplatin for gastric cancer with bulky and/or para-aortic lymph node metastases: A Japan Clinical Oncology Group Study (JCOG0405). Proc Am Soci Clin Oncol Gastolointestinal Meeting 2008 (Abstr No.118).
19. Yamaguchi K, Shimamura T, Hyodo I et al.: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1803-1808 (Pubitemid 43884569)
20. Takayama T, Sato Y, Sagawa T et al.: Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 2007; 97: 851-856. (Pubitemid 47519303)
21. Nakayama N, Koizumi W, Sasaki T, et al.: A multicenter phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008; 75: 1-7.